



HAL
open science

ANALYSIS OF THE HEALTH ECONOMIC IMPACT OF MEDICAL NUTRITION IN THE NETHERLANDS

Karen Freyer, Mark Nuijten

► **To cite this version:**

Karen Freyer, Mark Nuijten. ANALYSIS OF THE HEALTH ECONOMIC IMPACT OF MEDICAL NUTRITION IN THE NETHERLANDS. *European Journal of Clinical Nutrition*, 2010, 10.1038/ejcn.2010.147 . hal-00567030

HAL Id: hal-00567030

<https://hal.science/hal-00567030>

Submitted on 18 Feb 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**ANALYSIS OF THE HEALTH ECONOMIC IMPACT OF
MEDICAL NUTRITION IN THE NETHERLANDS**

FREIJER K¹, NUIJTEN MJC²

¹ BSc, Advanced Medical Nutrition, on behalf of the Dutch Industry of Children and Dietary Nutrition (VNFKD) Zoetermeer, The Netherlands

² PhD, MD, MBA, Ars Accessus Medica, Amsterdam, The Netherlands; Erasmus University Rotterdam, The Netherlands

Correspondence: Karen Freyer BSc, Health Economic & Market Access manager, Medical Department, Nutricia Advanced Medical Nutrition, Albert Einsteinlaan 20, 2719 EP, Postbus 445, 2700 AK Zoetermeer, The Netherlands. Phone: + 31 (0)79 353 96 79. Mob: +31 (0)6 21 81 27 36. E-mail: karen.freyer@nutricia.com

The publication of the study results was not contingent on the sponsor's approval.

Running Title: Analysis of the Health Economic Impact of Medical Nutrition in the Netherlands

ABSTRACT

Objective: A health economic analysis was performed to assess the cost-effectiveness of Oral Nutritional Supplements (ONS), being a medical nutrition product, in The Netherlands.

Methods: This analysis is based on a comparison of the use of ONS *versus* “no use” of ONS in patients undergoing abdominal surgery. The costs and benefits of the two treatment strategies were assessed using a linear decision analytic model reflecting treatment patterns and outcomes in abdominal surgery. The incremental cost difference was based on costs associated with ONS and hospitalization. Clinical probabilities and resource utilization were based on clinical trials and published literature; cost data were derived from official price tariffs.

Results: The use of ONS reduces the costs with a €252 (7.6%) cost saving per patient. The hospitalization costs reduce from €3,318 to €3,044 per patient, which is a 8.3% cost saving and corresponds with 0.72 days reduction in length of stay. The use of ONS would lead to an annual cost saving of a minimum of €40.4 million per year. Sensitivity analyses showed that the use of ONS remains cost saving compared to “no use” of ONS. A threshold analysis on the length of stay shows that at 0.64 days, the use of ONS is still cost-effective, which is an unrealistic value.

Conclusions: This analysis shows that the use of medical nutrition, ONS in this case, is a cost-effective treatment in The Netherlands and is dominant over standard care without medical nutrition: it leads to cost savings and a higher effectiveness.

Keywords: medical nutrition, cost-effectiveness, health economic model, oral nutritional supplements

INTRODUCTION

Nutritional depletion in Western countries is usually caused by the joint action of an underlying disease, e.g., cancer and dietary deficiency (Naber *et al.*, 1997), also known as Disease Related Malnutrition (DRM). As a consequence, treatment should be focused not only on the disease but also on nutritional intervention. A Dutch study found that 40% of the patients in a ward for nonsurgical patients were malnourished at admission, and that the risk of subsequent complications was higher in malnourished patients (Naber *et al.*, 1997). This frequency of DRM was as high as or higher than that reported in surgical patients (30%) (Naber *et al.*, 1997). This 40% percentage of DRM may be an underestimate because patients were excluded if nutritional status could not be assessed within 24 hours after admission. The consequences of malnutrition, if left untreated, are serious, causing a marked decline in physical and psychological health and function (Stratton & Elia, 2007). Malnutrition impairs recovery from disease and injury (including surgery), increasing mortality and complications (infections, pressure ulcers, etcetera) and healthcare use (general practitioners visits, length of stay) (Martyn *et al.*, 1998). Recently, also a burden of illness study was performed in The Netherlands (Tan & Koopmanschap, 2007). This study reports that the additional costs of disease related malnutrition in The Netherlands is €1,683 billion in 2006, which equals 2.8% of the total Dutch national health expenditures. The majority (49%) of the total costs on disease related costs were attributable to the hospital setting (€830 million).

Meta-analyses on treatment of DRM with medical nutrition show a reduction in mortality and complications, for example sepsis, decubitus and pneumonia, improvement of wound healing, and an increase of Quality of Life (www.snellerbeter.nl 2008; Elia *et al.*, 2005; Stratton, 2005). Stratton and Elia concluded that nutritional support can be an important part of the management of any patient (Stratton & Elia, 2007).

The published literature (meta-analyses and systematic reviews) provide evidence that oral nutritional supplements (ONS) are an effective treatment for patients with malnutrition:

- Mortality rates are significantly lower (odds ratio of 0.61; 95% CI 0.48-0.78) (Stratton & Elia, 2007). Similar findings were reported in other reviews (e.g. Potter, 2001).
- Complication rates, including infections, are significantly reduced (odds ratio of 0.31; 95% CI 0.17-0.56) (Stratton *et al.*, 2003; Stratton & Elia, 2007). Another systematic

review showed that medical nutrition can significantly reduce the risk (25% risk reduction) of developing pressure ulcers (Stratton *et al.*, 2005).

In summary, DRM has a high prevalence and its clinical consequences may be severe and costly. Consequently inappropriate management of DRM may have a high economic impact.

STUDY OBJECTIVES

The primary objective of this study was to assess the cost-effectiveness of ONS, being a medical nutrition product, in patients undergoing abdominal surgery in The Netherlands.

METHODS

A model was constructed using decision analytical techniques (Weinstein & Fineberg, 1980). This decision analytic model was developed to estimate the health economic impact of oral ONS in abdominal surgery from the perspective of the society in 2008 in the Netherlands. Data sources used included published literature, clinical trials and, official Dutch price/tariff lists and national population statistics.

Univariate sensitivity analyses are based on the modification of the basic clinical and economic assumptions in the model in order to test the stability of the conclusions of the analysis over a range of assumptions, probability estimates and value judgments.

- Proportion of malnutrition: The base case analysis (30%) is based on data for abdominal surgery; the range for the sensitivity analysis also includes data for non-surgical patients. The sensitivity analysis is based on a range varying from 25% to 40%.
- Proportion eligible patients: The base case analysis is based on the assumption that all malnourished patients are treated; a sensitivity analysis is based on a proportion of 50% of malnourished patients being treated with ONS.
- Cost of ONS: The cost of ONS is varied between 10% discount of the market price for inpatients (€2.19 per bottle) and an outpatient price including VAT (€2.37 per bottle).
- Cost of hospitalisation: The base case analysis is based on a weighted per diem cost for academic and general hospitals. A sensitivity analysis is performed varying the per diem between the per diem of a general hospital (€ 357) and the per diem of an academic hospital (€504).

- Duration of treatment with ONS: The base case analysis is based on a mean value of 8.5 days. A sensitivity analysis is performed varying the initiation from 7 to 16 days.
- Length of stay (LOS): A sensitivity analysis is based on a 25% decrease and increase of LOS for all patients (no risk and risk patients). This range was a subjective choice because of lack of data for the construction of a confidence interval. However, a 25% decrease and increase reduction of LOS can be considered a very extreme range and therefore captures the uncertainty in this input variable. A second sensitivity analysis was performed on a 25% decrease and increase of LOS for risk patients.

Model Design

The model calculates and compares the medical costs for a virtual population of abdominal surgery patients with ONS and for a virtual population of abdominal surgery patients without ONS. The health economic impact of ONS is calculated using a decision tree model built in TreeAge Pro 2005/2006 reflecting treatment patterns and outcomes in abdominal surgery. Figure 1 shows the structure of the model for treatment with ONS. The first branch point in a tree is called a decision node because it corresponds to a choice of treatment — ONS or “no ONS”. A decision node is represented as a small square (□). Subsequent to the decision node, the structure of the decision tree is shown, which is identical for both treatment options. The other branch points indicate probabilities. The patient may be at medium to high risk for DRM or at low risk for DRM.

Study Population and Comparison

The base case analysis is based on a comparison of the use of ONS *versus* “no use” of ONS in patients undergoing abdominal surgery.

Cost Assessment

An incremental costing approach was used, and therefore all drug utilisation (and other health care utilisation) being similar between the two treatment arms was not included in the model. The incremental cost difference was based on the costs associated with the cost of ONS and hospitalisation. The model is based on the assumption that the use of ONS only has an impact on the LOS. The potential favorable impact on adverse events by ONS and therefore the lower costs caused by adverse events were not included in this analysis, because of lack of appropriate data to feed the model. Thus the costing methodology is based on a conservative

approach towards the use of ONS. The real economic benefits will therefore be higher than could be calculated with the current data set (see Discussion). The perspective of the study was a limited societal perspective, because indirect costs were not included. Indirect costs due to productivity loss were not included in this health economic analysis. This is a conservative assumption towards the use of ONS, because the lower LOS would lead to lower productivity loss and therefore lower indirect costs. On the other hand, a substantial proportion of patients undergoing abdominal surgery may be retired, as the average age is 63.2 according to a Dutch study (Kruizenga *et al.*, 2003). Discounting of costs and effectiveness measures was not performed, because time horizon of the model did not exceed one year.

DATA SOURCES

The Number of Abdominal Surgery Procedures

A CBO publication reports the annual number of surgery procedures (1.3 million) in The Netherlands (www.cbo.nl, 2007). This is an overall number without defining the type of surgical procedure. The annual number of abdominal surgery procedures is 160,283. (Prismant, 2003).

Prevalence of Disease Related Malnutrition (DRM)

Several data on prevalence of DRM in the Netherlands have been published: from an overall prevalence of DRM of 25% (Kruizenga *et al.*, 2003) to a more group specific amount of 30% in surgical patients and 40% in non-surgical patients (Naber *et al.*, 1997):. A recent Dutch study reports a range on prevalence of DRM varying from 25% to 40% in hospitalised patients, including surgical and non-surgical patients (www.snellerbeter.nl, 2008). This report also states that only 50% of malnutrition is being diagnosed and treated. The most recent Dutch documentation is based on an annual returning independent measurement of the prevalence of DRM within the Dutch Health Care (Halfens *et al.*, 2006; Halfens *et al.*, 2007). The base case analysis is based on data from this Dutch documentation; the range for the sensitivity analysis also includes data for non-surgical patients. Therefore the base case analysis is based on a prevalence of DRM of 30% with a range varying from 25% to 40%. The base case analysis is based on the assumption that all malnourished patients are treated (eligible patients); a sensitivity analysis is based on the data from “Sneller Beter”, which reports that a proportion of 50% of malnourished patients is not treated with a ONS.

This input data for the Dutch model corresponds with the BAPEN study from the UK, although the prevalence of DRM is somewhat lower: 29.3% for patients older than 65 and 20.4% younger than 65 (Elia *et al.*, 2005). The UK data show that the difference in proportion of DRM is higher in the older patients (29.3% versus 20.4%). This difference is however less than 10%, which is much smaller than the range we use for the sensitivity analysis.

Length of Stay

An international observational study, including Dutch centers, evaluated the implementation of an enhanced recovery programme in five European centres and examined the determinants affecting recovery and LOS (Maessen *et al.*, 2007). This study showed that the median length of stay was 8 days for standard treatment. A multivariate analysis revealed no country specific effect on length of stay. Prismant data from 2003 reports an average length of stay of 12.9 days in abdominal surgery in The Netherlands (Prismant, 2003). For clinical outcomes, the general rule may be to assume that data are not country-specific (Nuijten, 1998). LOS in a hospital was considered a clinical outcome, which is not country-specific, which was also an essential assumption in the BAPEN report (Elia *et al.*, 2005).

Therefore international data on LOS were used in this analysis for a Dutch health economic evaluation of ONS.

The following data on LOS were reported in the BAPEN report, which is based on a 30% increase of LOS resulting from malnutrition:

Age of population (years)	LOS (days) when risk for DRM	LOS (days) when no risk for DRM
> 65	13.981	10.755
< 65	5.390	4.146

The base case analysis was based on a LOS of 8 days, based on the above mentioned international study, which included Dutch patients, whereas the 30% increase of LOS resulting from malnutrition was derived from the BAPEN report.

Recommended amount of intake of ONS

Typical prescription for ONS is 2 bottles (2 x 200 ml) per day per patient. The literature describes that 7 to 10 days before surgery the intake of ONS ought to be started, which may be continued until 7 to 10 days after surgery (McClave *et al.*, 1999; F.S.S.P.E.N., 1996; A.S.P.E.N., 2002). Therefore the base case analysis is based on a mean value of 8.5 days before and after surgery.

Costs of Treatment

Costs of ONS

The price of a standard bottle is €2.19, which corresponds with the list price as registered in the Dutch market. The costs for a hospital are lower due to discounts. The costs for a patient at the pharmacy are higher due to VAT. Therefore the most realistic price for a bottle would be €2.19.

Costs of hospitalisation

The cost of hospitalisation was derived from the Dutch Costing Manual (Oostenbrink *et al.*, 2004).

- Per diem academic hospital: €476
- Per diem general hospital: €337
- Distribution: academic hospital 16% and general hospital 84%

The costs were inflated from 2003 to 2008 (www.cbs.nl, 2008).

- Per diem academic hospital: €504
- Per diem general hospital: €357

RESULTS

Base case analysis

The results of the base case analysis are shown in Table 2. This analysis shows that the use of ONS does not lead to additional costs. In fact, the use of ONS reduces the costs from €3,318 to €3,066, which corresponds with a €252 (7.6%) cost saving per patient. The additional costs of ONS are more than balanced by a reduction on hospitalisation costs. The hospitalisation costs reduce from €3,318 to €3,044 per patient, which is a 8.3% cost saving and corresponds with 0.72 days reduction in LOS.

The use of ONS would lead to an annual cost saving of €40.4 million based on 160,283 abdominal procedures per year.

A scenario analysis was based on LOS of 12.9 days according to Prismant data (Prismant, 2003). In this analysis the use of ONS reduces the costs from €5,350 to €4,931, which corresponds with a €419 (7.8%) cost saving per patient.

Sensitivity analysis

The results of the sensitivity analyses are presented in Table 2. These results show that the use of ONS in all sensitivity analyses remains cost saving compared with “no use” of ONS.

Threshold analysis

Threshold analyses were performed in order to calculate the break even point for LOS and risk reduction at which the total costs for both treatment strategies are equal.

The first threshold analysis was performed on LOS. This analysis shows that the threshold for LOS is only 0.64 days. This value can be considered an unrealistic value compared with the actual length of stay in the UK. This would mean that even at a LOS of 1 day, the use of ONS is still cost-effective. As abdominal surgery requires at least two days of hospitalisation, this threshold analysis shows that the cost-effectiveness of ONS does not depend on local Dutch data on LOS. The second threshold analysis was performed on the increase of LOS for patients with malnutrition. This analysis shows that the threshold for the increase of LOS in risk patients is only 2.7%. This value also can be considered unrealistically low compared with the increase of 30% LOS in the UK. Therefore this threshold analysis shows that the cost-effectiveness of ONS does not depend on local Dutch data on reduction of LOS.

DISCUSSION

An analysis was performed for the use of ONS, being a medical nutrition product, in abdominal surgery in order to assess the health economic impact in The Netherlands. The rationale for performing this health economic analysis in abdominal surgery is that this is the most studied indication. The assumption of this study was that there were no clinical differences between the treatment arms, except for LOS. We have shown that the use of ONS is cost-effective, because:

1) Total costs for treatment with ONS are not higher than a treatment strategy without ONS: the additional costs for ONS are more than balanced by a reduction in hospitalisation costs due to a reduction in length of stay.

2) The analysis is based on similar clinical properties for both treatment strategies. However, the use of ONS is associated with a higher effectiveness, as this treatment leads to a reduction of the LOS.

Consequently, the use of ONS yields at least a similar effectiveness without extra costs and therefore can be considered cost-effective (position 1 in Figure 2). Even if we assume that there is no gain in effectiveness, the use of ONS remains cost-effective, as similar effectiveness is provided at lower costs. The results of this health economic analysis show that the use of ONS leads to lower treatment costs per patient and therefore can be considered cost-effective. The assumption for this health economic analysis is that there is no difference in mortality, complications and Quality of Life between the use of ONS, in this case ONS, *versus* “no use” of ONS in patients undergoing abdominal surgery. This is a conservative assumption towards the use of ONS, because meta-analyses show a reduction in mortality, complications and an improvement in Quality of Life (www.snellerbeter.nl, 2008; Elia *et al.*, 2005; Stratton, 2005). The real economic benefits for the use of ONS are therefore in fact higher than could be calculated with the current data set. A reduction of complications contributes considerably to a reduction in LOS and therefore would lower the costs. However we could not use these data in our model due to the fact that these outcomes for the studied patient group were not the primary ones. Indirect costs due to productivity loss were not included in this analysis. This is a conservative assumption towards the use of ONS, because the lower length of stay would lead to lower indirect costs. On the other hand, a substantial proportion of patients undergoing abdominal surgery may be retired. We may also expect that the use of ONS in fact leads to cost savings in other health care budgets: fewer complications during hospitalisations will also lead to fewer follow-up costs (readmissions, consultations, medication) (Gariballa *et al.*, 2006). Therefore we may conclude that this health economic is based on conservative assumptions for the use of ONS.

Sensitivity analyses were performed on all parameters, including length of stay and per diem costs. The results showed that the use of ONS in all sensitivity analyses remains cost saving compared to “no use” of ONS.

CONCLUSION

We performed a health economic analysis in order to assess the health economic impact of ONS in The Netherlands. This analysis was performed for the use of ONS, being a medical nutrition product, in abdominal surgery and showed that the use of ONS is cost-effective in the Dutch health care setting.

REFERENCES

- A.S.P.E.N. (2002). Guidelines for the Use of Parenteral and Enteral Nutrition in Adult and Pediatric Patients. *J.P.E.N.* **26**, Suppl, 1SA-138 SA.
- Elia M, Stratton R, Russel C, Green C and Pang F (2005): The cost of disease related malnutrition in the UK and economic considerations for the use of oral nutritional supplements in adults. *Health Economic Report on Malnutrition in the UK*. BAPEN.
- Elia M, Zellipour L and Stratton RJ (2005): To screen or not to screen for adult malnutrition? *Clin. Nutr.* **24**, 867-884.
- F.S.S.P.E.N. French Speaking Society for Parenteral and Enteral Nutrition (1996): Perioperative artificial nutrition in elective adult surgery. *Clin. Nutr.* **15**, 223-229.
- Gariballa S, Forster S, Walters S, Powers H (2006). A randomized double-blind placebo-controlled trial of nutritional supplementation during acute illness. *Am J Med.* **119**, 693-699.
- Halfens RJG, Janssen MAP and Meijers JMM (2006): Ondervoeding. In *Rapportage resultaten. Landelijke prevalentiemeting zorgproblemen 2006*, Universiteit Maastricht Zorgwetenschappen sectie Verplegingswetenschap, pp 79-101. Maastricht: Universitaire pers Maastricht.
- Halfens RJG, Meijers JMM, Neyens JCL and Offermans MPJ (2007): Ondervoeding. In *Rapportage resultaten. Landelijke prevalentiemeting zorgproblemen 2007*, Universiteit Maastricht Onderzoeksinstituut Caphri Department of Health Care and Nursing Sciences, pp 81-108. Maastricht: Universitaire pers Maastricht.
- Kruizenga HM, Wierdsma NJ, van Bokhorst –de van der Schueren MAE, Hollander HJ, Jonkers-Schuitema CF and van der Heijden E *et al* (2003): Screening of nutritional status in The Netherlands. *Clin. Nutr.* **22**, 147-152.
- Maessen J, Dejong CHD, Hausel J, Nygren J, Lassen K, Andersen J *et al* (2007): A protocol is not enough to implement an enhanced recovery programme for colorectal resection. *Br. J. Surg.* **94**, 224-231.
- Martyn CN, Winter PD, Coles SJ and Edington J (1998): Effect of nutritional status on use of health care resources by patients with chronic disease living in the community. *Clin. Nutr.* **17**, 119-123.
- McClave SA, Snider HL and Spain DA (1999): Preoperative Issues in Clinical Nutrition. *CHEST* **115**, 64S-70S.
- Naber TH, Schermer T, de Bree A, Nusteling K, Eggink L, Kruimel JW *et al* (1997): Prevalence of malnutrition in nonsurgical hospitalized patients and its association with disease complications. *Am. J. Clin. Nutr.* **66**, 1232-1239.
- Nuijten MJ (1998): The selection of data sources for use in modelling studies. *Pharmacoeconomics.* **13**, 305-16.
- Oostenbrink JB, Bouwmans CAM, Koopmanschap MA. Rutten FFH. Handleiding voor kostenonderzoek. Geactualiseerde versie 2004. CVZ. Diemen.
- Potter JM (2001): Oral supplements in the elderly. *Curr. Opin. Clin. Nutr. Metab. Care* **4**, 21-28.

Prismant 2003. Data on number of hospitalisations and length of stay.

Stratton RJ (2005): Elucidating effective ways to identify and treat malnutrition. *Proc. Nutr. Soc.* **64**, 305-311.

Stratton RJ and Elia M (2007): Who benefits from nutritional support: what is the evidence? *Eur. J. Gastroenterol. Hepatol.* **19**, 353-358.

Stratton RJ, Ek AC, Engfer M, Moore Z, Rigby P, Wolfe R *et al* (2005): Enteral nutritional support in prevention and treatment of pressure ulcers: a systematic review and meta-analysis. *Ageing Res. Rev.* **4**, 422-50.

Stratton RJ, Green CJ and Elia M (2003): Disease-related malnutrition: an evidenced based approach to treatment. Oxford: CABI Publishing.

Tan Siok Swan and Koopmanschap Marc (2007): The cost of disease related malnutrition and the cost-effectiveness of nutrition interventions: a feasibility study for the Netherlands. *Data on file*.

Weinstein MC and Fineberg HV (1980): Clinical decision Analysis. Philadelphia, Pa: WB Saunders Co pp 228-265.

www.cbo.nl; Richtlijn Perioperatief voedingsbeleid (2007). Kwaliteitsinstituut voor de Gezondheidszorg CBO.

www.cbs.nl; nl-NL/menu/cijfers/default.htm

www.snellerbeter.nl; ACHTERGRONDINFORMATIE: Implementatie van vroege herkenning & behandeling van ondervoeding in de kliniek en op de polikliniek in Nederlandse ziekenhuizen. www.snellerbeter.nl/fileadmin/snellerbeter/documenten/Ondervoeding/19projectplan_maasziekenhuis_pantein.doc. Accessed may 12.2008.

Figure 1: Model for the use of ONS in abdominal surgery.

Figure 2: Cost-effectiveness diagram.

Table 1: Results: base case results and sensitivity analyses.

	range	ONS	no ONS	savings
base case		€3,066	€3,318	€252
proportion malnutrition	25%	€3,063	€3,318	€255
	40%	€3,074	€3,318	€244
eligible	50%	€3,192	€3,318	€126
price ONS	1.97	€3,064	€3,318	€254
	2.37	€3,068	€3,318	€250
cost hospitalisation	357	€2,878	€3,113	€235
	504	€4,054	€4,395	€341
use of ONS before and after operation	7	€3,063	€3,318	€255
	10	€3,070	€3,318	€248
length of stay all patients	-25%	€2,305	€2,489	€184
	25%	€3,828	€4,148	€320
length of stay only risk	-25%	€2,838	€3,021	€183
	25%	€3,295	€3,615	€320
		€3,066	€3,318	€252

Table 2: Results of two-way sensitivity analyses.

sens						
=>	0,7500	0,8750	10,000	11,250	12,500	
Risk_LOS_nosupply_larger						
15,000	€2,305	€2,610	€1,914	€3,218	€3,523	FSMP
	€2,626	€2,976	€3,326	€3,676	€4,026	No FSMP
	€321	€366	€1,412	€458	€503	Savings
13,875	€2,305	€2,610	€2,914	€3,219	€3,523	FSMP
	€2,549	€2,888	€3,228	€3,568	€3,908	No FSMP
	€243	€278	€314	€349	€385	Savings
12,750	€2,305	€2,610	€2,914	€3,219	€3,523	FSMP
	€2,471	€2,801	€3,131	€3,460	€3,790	No FSMP
	€166	€191	€217	€241	€266	Savings
11,625	€2,305	€2,610	€2,914	€3,219	€3,523	FSMP
	€2,394	€2,714	€3,033	€3,352	€3,671	No FSMP
	€89	€104	€119	€133	€148	Savings
10,500	€2,305	€2,610	€2,914	€3,219	€3,523	FSMP
	€2,317	€2,626	€2,935	€3,244	€3,553	No FSMP
	€12	€16	€21	€26	€30	Savings

abdominal surgey

ONS

medium + high risk

p_risk_ONS

cost_hospitalisation_risk+cost_ONS

low risk

1-p_risk_ONS

cost_hospitalisation_no_risk

no ONS

medium + high risk


p_risk_no_ONS

cost_hospitalisation_risk


low risk

1-p_risk_no_ONS

cost_hospitalisation_no_risk



Effectiveness



Total costs